Patents by Inventor Bing Shi

Bing Shi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
    Patent number: 10730879
    Abstract: Polymorphs of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one, compositions thereof, methods for their preparation, and methods for their use are disclosed.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: August 4, 2020
    Assignee: Gilead Calistoga LLC
    Inventors: Ernest Carra, Michael Gerber, Bing Shi, Keiko Sujino, Duong Tran, Fang Wang, Jerry B. Evarts
  • Methods and intermediates for preparing therapeutic compounds
    Patent number: 10696657
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: June 30, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Amanda L. Vandehey, Gediminas Brizgys, Vinh X. Ngo, Brian M. O'Keefe, Trevor J. Rainey, Bing Shi, Winston C. Tse, Anna M. Wagner, Xianghong Wang, Scott A. Wolckenhauer, Chloe Y. Wong
  • Solid forms of an antiviral compound
    Patent number: 10604530
    Abstract: Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4?,3?:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using these crystalline forms.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: March 31, 2020
    Assignee: Gilead Pharmasset LLC
    Inventors: Olga Viktorovna Lapina, Bing Shi, Fang Wang, Scott Alan Wolckenhauer
  • METHODS AND INTERMEDIATES FOR PREPARING THERAPEUTIC COMPOUNDS
    Publication number: 20190300505
    Abstract: The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
    Type: Application
    Filed: February 15, 2019
    Publication date: October 3, 2019
    Inventors: Kevin McCormack Allan, Amanda Lynn Batten, Gediminas Brizgys, Sachin Dhar, Ian James Doxsee, Alex Goldberg, Lars V. Heumann, Zilin Huang, Nathaniel Thomas Kadunce, Shahrokh Kazerani, Willard Lew, Vinh Xuan Ngo, Brian Michael O'Keefe, Trevor James Rainey, Benjamin James Roberts, Bing Shi, Dietrich P. Steinhuebel, Winston C. Tse, Anna Michelle Wagner, Xianghong Wang, Scott Alan Wolckenhauer, Chloe Yuyi Wong, Jennifer R. Zhang
  • Crystalline forms of darunavir
    Patent number: 10407438
    Abstract: The present invention relates to novel crystalline forms of darunavir, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: September 10, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Chiajen Lai, Bing Shi
  • POLYMORPH OF TRIARYLDIMETHYLPIPERAZINE DIHYDROCHLORIDE AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20190270720
    Abstract: The application discloses five polymorph forms B, P, F, J, O of (4-((R)-((2S,5R)-4-(3-fluorobenzyl)-(2,5-dimethylpiperazine-1-yl)(3-hydroxyphenyl)methyl)phenyl)(4-methylpiperidine-1-yl)methanone dihydrochloride, preparation methods thereof and application thereof in the manufacture of a medicament for preventing or treating a mood disorder or a disease related to a ? opioid receptor.
    Type: Application
    Filed: November 21, 2016
    Publication date: September 5, 2019
    Applicant: Yunnan Institute of Materia Medica
    Inventors: Jingkun Wang, Zhaoyun Zhu, He Song, Min Sun, Tao Cui, Zeren Wang, Zhi Yang, Min Su, Hongbin Liu, Bing Shi, Yong Mao, Huilang Liu, Zeqian Li, Chunmei Zhao, Mei Su, Fang Yuan, Tiancai Zhang, Yong Liu, Kuanren Zhang, Yunlin Wei, Yuehai Shen
  • SOLID FORMS OF AN ANTIVIRAL COMPOUND
    Publication number: 20190270750
    Abstract: Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4?,3?:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3 -methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using these crystalline forms.
    Type: Application
    Filed: December 18, 2017
    Publication date: September 5, 2019
    Inventors: Olga Viktorovna Lapina, Bing Shi, Fang Wang, Scott Alan Wolckenhauer
  • Inhibitors of bruton'S tyrosine kinase
    Patent number: 10370381
    Abstract: Provided are forms of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, compositions thereof, methods for their preparation, and methods for their use.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: August 6, 2019
    Assignee: Gilead Sciences, Inc.
    Inventor: Bing Shi
  • CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE
    Publication number: 20190233448
    Abstract: The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Application
    Filed: March 21, 2019
    Publication date: August 1, 2019
    Inventors: Chiajen Lai, Bing Shi, Robert G. Strickley
  • Crystalline forms of tenofovir alafenamide
    Patent number: 10287307
    Abstract: The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: May 14, 2019
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Chiajen Lai, Bing Shi, Robert G. Strickley
  • Choline salt forms of an HIV capsid inhibitor
    Publication number: 20190083478
    Abstract: The present disclosure relates to choline salts, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1 -yl)pyridin-2-yl)-2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment and prevention of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: August 16, 2018
    Publication date: March 21, 2019
    Inventors: Travis Lee Houston, Bing Shi
  • Solid Forms Of an HIV Capsid Inhibitor
    Publication number: 20190084963
    Abstract: The present disclosure relates to pharmaceutically acceptable salts, cocrystals, and crystalline forms thereof, of a compound which is N—((S)-1-(3-(4-chloro-3-(methylsulfonamido)-1-(2,2,2-trifluoroethyl)-1H-indazol-7-yl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1 -yl)pyridin-2-yl)-2-(3,5-difluorophenypethyl)-2- ((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamide, which is useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.
    Type: Application
    Filed: August 16, 2018
    Publication date: March 21, 2019
    Inventor: Bing Shi
  • CRYSTALLINE FORMS OF ETHYL ((S)-((((2R,5R)-5-(6-AMINO-9H-PURIN-9-YL)-4-FLUORO-2,5-DIHYDROFURAN-2-YL)OXY)METHYL)(PHENOXY)PHOSPHORYL)-L-ALANINATE
    Publication number: 20190040092
    Abstract: The present invention relates to novel forms of ethyl ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-L-alaninate, pharmaceutical formulations, and therapeutic uses thereof in treating viral infections (e.g., an HIV infection).
    Type: Application
    Filed: July 30, 2018
    Publication date: February 7, 2019
    Inventors: Olga Viktorovna Lapina, Bing Shi, Silas Wang
  • Co-crystals, salts and solid forms of tenofovir alafenamide
    Patent number: 10155781
    Abstract: The present invention relates to co-crystals, salts and crystalline forms of tenofovir alafenamide and methods for preparation, use and isolation of such compounds.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 18, 2018
    Assignee: Gilead Sciences, Inc.
    Inventors: Bing Shi, Zhuoyi Su, Fang Wang
  • CRYSTALLINE FORMS OF TENOFOVIR ALAFENAMIDE
    Publication number: 20180265530
    Abstract: The present invention relates to novel crystalline forms of salts and/or co-crystals of tenofovir alafenamide, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Application
    Filed: January 29, 2018
    Publication date: September 20, 2018
    Inventors: Chiajen Lai, Bing Shi, Robert G. Strickley
  • INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20180251464
    Abstract: Provided are forms of 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one, compositions thereof, methods for their preparation, and methods for their use.
    Type: Application
    Filed: February 23, 2018
    Publication date: September 6, 2018
    Inventor: Bing Shi
  • CRYSTALLINE FORMS OF DARUNAVIR
    Publication number: 20180170945
    Abstract: The present invention relates to novel crystalline forms of darunavir, the pharmaceutical formulations, and the therapeutic uses thereof in treating viral infections.
    Type: Application
    Filed: October 25, 2017
    Publication date: June 21, 2018
    Inventors: Chiajen Lai, Bing Shi
  • CO-CRYSTALS, SALTS AND SOLID FORMS OF TENOFOVIR ALAFENAMIDE
    Publication number: 20180127446
    Abstract: The present invention relates to co-crystals, salts and crystalline forms of tenofovir alafenamide and methods for preparation, use and isolation of such compounds
    Type: Application
    Filed: September 5, 2017
    Publication date: May 10, 2018
    Inventors: Bing Shi, Zhuoyi Su, Fang Wang
  • Solid forms of an antiviral compound
    Patent number: 9884873
    Abstract: Crystalline solid forms of methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}-1,11-dihydroisochromeno[4?,3?:6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using these crystalline forms.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: February 6, 2018
    Assignee: Gilead Pharmasset LLC
    Inventors: Olga Viktorovna Lapina, Bing Shi, Fang Wang, Scott Alan Wolckenhauer
  • SOLID FORMS OF AN ANTIVIRAL COMPOUND
    Publication number: 20170327488
    Abstract: Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 16, 2017
    Inventors: Erik Mogalian, Robert William Scott, Bing Shi, Fang Wang